Loading…
RIVA-ROSUVASTATIN is a brand name for Rosuvastatin, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Verbatim from this product's HC label. Tap a section to expand.
2 Breast feeding 02/2025 TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES .......................................................................................... 2 TABLE OF CONTENTS ............................................................................................................
2 PART 1: HEALTHCARE PROFESSIONAL INFORMATION ........................................................... 4 1. INDICATIONS .................................................................................................................
1. Pediatrics.................................................................................................................... 2. Geriatrics ....................................................................................................................
4 2. CONTRAINDICATIONS .................................................................................................... 4 4. DOSAGE AND ADMINISTRATION ....................................................................................
1. Dosing Considerations ............................................................................................... 2. Recommended Dose and Dosage Adjustment .......................................................... 4. Administration ...........................................................................................................
5. Missed Dose ............................................................................................................... 7 5. OVERDOSE ....................................................................................................................
7 6. DOSAGE FORMS, STRENGTHS, COMPOSITION, AND PACKAGING .................................... 8 7. WARNINGS AND PRECAUTIONS ..................................................................................... 1. Special Populations ..................................................................................................
1. Pregnancy......................................................................................................... 2. Breast feeding ..................................................................................................
3. Pediatrics.......................................................................................................... 4. Geriatrics ..........................................................................................................
13 RIVA-ROSUVASTATIN (Rosuvastatin calcium Tablets) Product Monograph Page 3 of 47 8. ADVERSE REACTIONS ................................................................................................... 1. Adverse Reaction Overview .....................................................................................
).
Lipoprotein(a):
In some patients, the beneficial effect of lowered total cholesterol and LDL-C levels may be partly blunted by a concomitant increase in the Lipoprotein(a) [Lp(a)] concentrations. Present knowledge suggests the importance of high Lp(a) levels as an emerging risk factor for coronary heart disease.
It is thus desirable to maintain and reinforce lifestyle changes in high risk patients placed on rosuvastatin therapy.
Genetic Polymorphism:
In patients with SLCO1B1 (OATP1B1) and/or ABCG2 (BCRP) genetic polymorphisms there is a risk of increased rosuvastatin exposure (see
2 Breast feeding 02/2025 TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES .......................................................................................... 2 TABLE OF CONTENTS ............................................................................................................
2 PART 1: HEALTHCARE PROFESSIONAL INFORMATION ........................................................... 4 1. INDICATIONS .................................................................................................................
1. Pediatrics.................................................................................................................... 2. Geriatrics ....................................................................................................................
4 2. CONTRAINDICATIONS .................................................................................................... 4 4. DOSAGE AND ADMINISTRATION ....................................................................................
1. Dosing Considerations ............................................................................................... 2. Recommended Dose and Dosage Adjustment .......................................................... 4. Administration ...........................................................................................................
5. Missed Dose ............................................................................................................... 7 5. OVERDOSE ....................................................................................................................
7 6. DOSAGE FORMS, STRENGTHS, COMPOSITION, AND PACKAGING .................................... 8 7. WARNINGS AND PRECAUTIONS ..................................................................................... 1. Special Populations ..................................................................................................
07/2024 2 CONTRAINDICATIONS 02/2025
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Rosuvastatin in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
2. Clinical Trial Adverse Reactions ............................................................................... 1. Clinical Trial Adverse Reactions – Pediatrics.................................................... 3. Less Common Clinical Trial Adverse Reactions ........................................................
4.
Abnormal Laboratory Findings:
Hematologic, Clinical Chemistry, and Other Quantitative Data ................................................................................................................. 5. Post-Market Adverse Reactions...............................................................................
17 9. DRUG INTERACTIONS .................................................................................................. 1. Serious Drug Interactions ........................................................................................
2. Drug Interactions Overview ..................................................................................... 3. Drug-Behaviour Interactions.................................................................................... 4. Drug-Drug Interactions ............................................................................................
5. Drug-Food Interactions ............................................................................................ 6. Drug-Herb Interactions ............................................................................................
7. Drug-Laboratory Test Interactions........................................................................... 26 10. CLINICAL PHARMACOLOGY .......................................................................................... 1. Mechanism of Action ...............................................................................................
2. Pharmacodynamics .................................................................................................. 3. Pharmacokinetics .....................................................................................................
27 11. STORAGE, STABILITY, AND DISPOSAL ............................................................................ 28 12. SPECIAL HANDLING INSTRUCTIONS .............................................................................. 28 PART 2: SCIENTIFIC INFORMATION .....................................................................................
29 13. PHARMACEUTICAL INFORMATION […]
1. Pregnancy......................................................................................................... 2. Breast feeding ..................................................................................................
3. Pediatrics.......................................................................................................... 4. Geriatrics ..........................................................................................................
13 RIVA-ROSUVASTATIN (Rosuvastatin calcium Tablets) Product Monograph Page 3 of 47 8. ADVERSE REACTIONS ................................................................................................... 1. Adverse Reaction Overview .....................................................................................
2. Clinical Trial Adverse Reactions ............................................................................... 1. Clinical Trial Adverse Reactions – Pediatrics.................................................... 3. Less Common Clinical Trial Adverse Reactions ........................................................
4.
Abnormal Laboratory Findings:
Hematologic, Clinical Chemistry, and Other Quantitative Data ................................................................................................................. 5. Post-Market Adverse Reactions...............................................................................
17 9. DRUG INTERACTIONS .................................................................................................. 1. Serious Drug Interactions ........................................................................................
2. Drug Interactions Overview ..................................................................................... 3. Drug-Behaviour Interactions.................................................................................... 4. Drug-Drug Interactions ............................................................................................
5. Drug-Food Interactions ............................................................................................ 6. Drug-Herb Interactions ............................................................................................
7. Drug-Laboratory Test Interactions........................................................................... 26 10. CLINICAL PHARMACOLOGY .......................................................................................... 1. Mechanism of Action ...............................................................................................
2. Pharmacodynamics .................................................................................................. 3. Pharmacokinetics .....................................................................................................
27 11. STORAGE, STABILITY, AND DISPOSAL ............................................................................ 28 12. SPECIAL HANDLING INSTRUCTIONS .............................................................................. 28 PART 2: SCIENTIFIC INFORMATION .....................................................................................
29 13. PHARMACEUTICAL INFORMATION ............................................................................... 29 14. CLINICAL TRIALS ..........................................................................................................
1. Clinical Trials by Indication […]